বাংলায় দেখুন
💊

Recepra

Powder for Suspension

🧬 Cephradine 🏢 Reliance Pharmaceuticals Ltd.
Generic Name Cephradine
Manufacturer Reliance Pharmaceuticals Ltd.
Unit Price 100 ml bottle: ৳ 75.00

🔹 Indications

Recepra is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Recepra:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Recepra which is unaffected by this enzyme.

🔹 Pharmacology

Recepra is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Recepra:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Recepra which is unaffected by this enzyme.

🔹 Dosage & Administration

Recepra is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Recepra:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Recepra which is unaffected by this enzyme.

🔹 Interaction

Recepra is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Recepra:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Recepra which is unaffected by this enzyme.

🔹 Contraindications

Recepra is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Recepra:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Recepra which is unaffected by this enzyme.

🔹 Side Effects

Recepra is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Recepra:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Recepra which is unaffected by this enzyme.

🔹 Pregnancy & Lactation

Recepra is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Recepra:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Recepra which is unaffected by this enzyme.

🔹 Precautions & Warnings

Recepra is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include-
  • Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media, and also
  • Lower respiratory tract infections: bronchitis (acute and chronic), lobar pneumonia and bronchopneumonia.
  • Urinary tract infections: cystitis, urethritis and pyelonephritis.
  • Skin and soft tissue infections: abscess, cellulitis, furunculosis and impetigo.
The following microorganisms are susceptible, in vitro to Recepra:
  • Gram-positive: Staphylococci (both penicillin sensitive and resistant strains and penicillinase-producing species), Streptococci, Streptococci pyogenes (beta haemolytic), Streptococcus pneumonia.
  • Gram-negative: Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenza, Shigella spp, Salmonella spp (including Salmonella typhi), Neisseria spp Many strains of E.coli and Staphylococcus aureus that produce the enzyme penicillinase and thus are ampicillin resistant, are susceptible to Recepra which is unaffected by this enzyme.

💡 Frequently Asked Questions

Recepra is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include- Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and oti...
Recepra is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include- Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and oti...
Recepra is indicated for the treatment of infections caused by sensitive Gram-positive and Gram-negative bacteria. These include- Undesirable Upper respiratory tract infections: sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and oti...

User Reviews

No reviews yet!
Be the first to share your experience.

Write a Review